Georgia Life Sciences Association Statement on the Release of the NSCEB Final Report and Action Plan

Emerging biotechnology is key for U.S. to remain dominant and secure future economic growth in a new era of global competition

Georgia Life Sciences (GLS) applauds the National Security Commission on Emerging Biotechnology (NSCEB) for its leadership and vision in publishing its final report and action plan to Congress. This comprehensive roadmap is a vital step toward securing and advancing U.S. leadership in biotechnology at a critical moment for our nation's competitiveness, security, and economic future.


We strongly support the Commission’s call for urgent federal action, including the proposed $15 billion in new investments over five years, to ensure the U.S. biotechnology sector remains the global leader in innovation and commercialization. These resources will help drive transformative advances across healthcare, manufacturing, national security, and more.


The timing of this report is especially critical as our nation’s life sciences research and innovation infrastructure, particularly at the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), faces considerable uncertainty. Strong federal leadership and investment are essential to maintain the momentum of discovery, innovation, and public health progress.


The report’s 49 recommendations, organized across six strategic pillars, offer a bold and actionable framework:

  • Prioritize biotechnology at the national level
  • Mobilize the private sector to get U.S. products to scale
  • Maximize the benefits of biotechnology for defense
  • Out-innovate our strategic competitors
  • Build the biotechnology workforce of the future
  • Mobilize the collective strengths of our allies and partners


Georgia Life Sciences encourages members of the Georgia congressional delegation to endorse the Commission’s report and advocate for its swift and full implementation by the administration. Georgia's leadership in life sciences innovation positions our state to be a key contributor in realizing the report’s vision, and federal support is essential to maximizing this opportunity for both regional and national impact.


As Georgia continues to grow its vibrant life sciences ecosystem, we recognize the immense potential of a coordinated national strategy to accelerate innovation, empower our workforce, and foster public-private partnerships. We look forward to working with policymakers, industry partners, and research institutions to implement these recommendations and deliver biotechnology solutions that improve lives and strengthen our country. As the report states, without this type of transformational investment, our adversaries will work to leverage their biotech advancements to attack, destroy, starve, and harm the U.S.


The full text of the final report can be found here: https://biotech.senate.gov 

Announcement: https://www.biotech.senate.gov/press-releases/nsceb-publishes-final-report/

BIO's statement is here.

March 24, 2026
Georgia Life Sciences is proud to be featured in the latest issue of Inside Medicine Magazine – Atlanta, highlighting the continued growth and impact of Georgia’s life sciences ecosystem.This inaugural issue represents something truly special. Atlanta’s healthcare and life sciences community is driven by innovation, collaboration, and outstanding leadership—and we’re honored to be part of this exciting launch. We’re proud to help showcase the people and organizations advancing healthcare across our region and beyond. Read our feature here: https://hubs.la/Q04876WJ0
March 24, 2026
B y Trevor Williams , March 24, 2026 | Global Atlanta More than 60 Belgian firms have found a home in Georgia, but nothing on this scale has yet been seen in the state. The amalgam of Belgian investment, carried out over a half-century, translates to about 5,000 current jobs. Gwinnett offered $174 million in incentives to win the project, including property tax abatements, fee waivers and utility improvements, according to Rowen. UCB is set to bring in artificial intelligence, advanced robotics and automation at the site. Biologics are therapies made from living organisms, promising cutting-edge research and manufacturing. Maria Thacker Goethe , president and CEO of Georgia Life Sciences , said the move gives state leaders even more impetus to work collaboratively to build Georgia’s talent pipeline “across every stage — from high school exposure and technical credentials to community college, university, and incumbent-worker upskilling.” “UCB’s decision underscores the strength of Georgia’s talent base, manufacturing capacity, and collaborative business climate, and it reflects the kind of long-term investment that helps build a more resilient U.S. biomanufacturing footprint,” Ms. Goethe told Global Atlanta in an email. Nine of the 16 FDA approvals for UCB drugs and therapies have come within the last three years, showing its prioritization of the U.S. market, where headcount has grown 73 percent since 2017 to 2,000 people. UCB’s products treat severe neurological and immunological conditions like epilepsy, lupus, Parkinson’s disease, rheumatoid arthritis and many more. Read the full article here: UCB Sticks With Georgia, Placing $2 Billion Bet on State’s Life Sciences Ecosystem - Global Atlanta
March 17, 2026
Georgia Life Sciences leads effort to establish bipartisan caucus focused on advancing the state’s growing life sciences economy
MORE POSTS